Why is Karyopharm Therapeutics stock collapsing over 60% today?
Karyopharm Therapeutics shares fell about 67% to $2.29 after its Phase 3 XPORT-EC-042 endometrial cancer trial missed its primary goal, with no statistically significant progression-free survival improvement versus placebo. Analysts downgraded and cut price targets (e.g., Baird $15 to $3, H.C. Wainwright $13 to $3). Karyopharm said it will scale back endometrial plans and focus on myelofibrosis and multiple myeloma.
How this was made
The 30-second read
Why it matters
The primary endpoint miss triggered immediate pipeline devaluation, investment scaling back, and rapid analyst downgrades with sharply reduced price targets. A separate planned supplemental NDA for selinexor plus ruxolitinib in myelofibrosis is a later catalyst but is not enough to offset the trial failure in the near term.
Market read
This is a same-day, company-specific repricing event driven by a Phase 3 primary endpoint miss and cascading sell-side target cuts.
What to watch
Market reaction may over-discount the myelofibrosis franchise ahead of the August 2026 FDA submission details, including Priority Review likelihood and the strength of supporting data.
Background
Karyopharm reported Phase 3 results for selinexor as maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer.
Ticker impact
Karyopharm’s Phase 3 XPORT-EC-042 endometrial cancer trial missed its primary progression-free survival goal, driving a 67%+ selloff and analyst target cuts.
Further downside risk remains elevated until FDA/clinical readouts clarify the probability-weighted value of the myelofibrosis program.
The article cites a statistically significant miss versus placebo, immediate investment scaling back, and multiple analyst downgrades with large price-target reductions, which typically sustains negative repricing even if a later regulatory filing is planned.
Market effects
Reinforces risk premium for oncology late-stage trial outcomes and can pressure sentiment toward similar selinexor or TP53 wild-type endometrial cancer strategies.
Limited direct regional spillover; the article frames broader US indices as modestly lower.
Primarily US biotech-specific sentiment, with limited evidence of cross-market contagion beyond risk appetite.
Counterpoint
The numerical trend favoring selinexor and the planned supplemental NDA for myelofibrosis could support a rebound if investors believe the failure was program-specific rather than platform-wide.
Key entities
- companyKaryopharm Therapeutics
Subject of the article, with a Phase 3 trial miss and planned supplemental NDA filing.
- regulatorFDA
Receives the planned supplemental New Drug Application in August 2026 for an accelerated approval pathway.
- analyst_firmBaird
Downgraded Karyopharm from Outperform to Neutral and cut its price target to $3.00.
- analyst_firmH.C. Wainwright
Moved from Buy to Neutral and reduced its price target to $3.00.
